UPDATE: Piper Jaffray Lowers Accretive Health's PT

Loading...
Loading...
According to a research report published this morning, Piper Jaffray has lowered Accretive Health's
AH
PT from $12 to $8. In the report, Piper Jaffray said, "Over the Weekend, Fairview dropped Accretive health for its QTCOC contract, Senator Al Franken vowed to investigate the activities of Accretive Health, a local newspaper reported questionable financial ties to the Company by key Fairview executives, and the Company vehemently denied the allegations made by MN Attorney General. We believe the recent events pose a risk to customer renewals, new contract wins, and recognition of incentive revenues if the Company must tone down the rhetoric. We are lowering our estimates and price target to $8, reiterate Underweight rating." Accretive Health is currently trading at $9.30.
Posted In: Analyst ColorPrice TargetAnalyst RatingsPiper Jaffray
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...